Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating ...

Unless you’re a die-hard tinkerer, PC maintenance probably feels as much of a chore as servicing your car. Fortunately, ...

The allure of a pre-owned Samsung phone is undeniable: top-tier specs at a fraction of the cost. However, with used devices ...

Dengue virus infections can result in a range of clinical manifestations from asymptomatic infection to dengue fever (DF) and the severe disease dengue haemorrhagic fever/dengue shock syndrome ...

All but one of included studies used diagnostic case–control designs. The summary estimates from the exploratory meta-analysis need to be interpreted very cautiously. We were unable to test all but ...

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic ...

Affinity Technologie announced that the Australian Patent Office or IP Australia, has accepted bioAffinity’s patent application for the ...

NOWDiagnostics, Inc. (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, proudly ...